Tibet Rhodiola Pharmaceutical Holding Past Earnings Performance
Past criteria checks 6/6
Tibet Rhodiola Pharmaceutical Holding has been growing earnings at an average annual rate of 20.8%, while the Healthcare industry saw earnings growing at 4.2% annually. Revenues have been growing at an average rate of 22.7% per year. Tibet Rhodiola Pharmaceutical Holding's return on equity is 22.2%, and it has net margins of 27.7%.
Key information
20.8%
Earnings growth rate
20.5%
EPS growth rate
| Healthcare Industry Growth | 7.0% |
| Revenue growth rate | 22.7% |
| Return on equity | 22.2% |
| Net Margin | 27.7% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Tibet Rhodiola Pharmaceutical Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,932 | 811 | 1,771 | 16 |
| 31 Dec 23 | 3,134 | 801 | 1,881 | 17 |
| 30 Sep 23 | 2,964 | 782 | 1,793 | 17 |
| 30 Jun 23 | 3,032 | 703 | 1,818 | 19 |
| 31 Mar 23 | 2,805 | 498 | 1,685 | 83 |
| 31 Dec 22 | 2,555 | 370 | 1,541 | 88 |
| 30 Sep 22 | 2,535 | 233 | 1,533 | 122 |
| 30 Jun 22 | 2,444 | 173 | 1,466 | 133 |
| 31 Mar 22 | 2,300 | 226 | 1,366 | 69 |
| 31 Dec 21 | 2,139 | 209 | 1,253 | 61 |
| 30 Sep 21 | 1,945 | 512 | 1,113 | 23 |
| 30 Jun 21 | 1,782 | 496 | 1,014 | 10 |
| 31 Mar 21 | 1,571 | 447 | 884 | 8 |
| 31 Dec 20 | 1,373 | 418 | 748 | 7 |
| 30 Sep 20 | 1,314 | 398 | 704 | 7 |
| 30 Jun 20 | 1,266 | 375 | 670 | 10 |
| 31 Mar 20 | 1,256 | 370 | 658 | 9 |
| 31 Dec 19 | 1,256 | 312 | 682 | 11 |
| 30 Sep 19 | 1,218 | 224 | 670 | 11 |
| 30 Jun 19 | 1,194 | 243 | 641 | 9 |
| 31 Mar 19 | 1,112 | 218 | 594 | 11 |
| 31 Dec 18 | 1,028 | 216 | 548 | 8 |
| 30 Sep 18 | 1,014 | 326 | 492 | 9 |
| 30 Jun 18 | 933 | 301 | 455 | 8 |
| 31 Mar 18 | 883 | 244 | 427 | 5 |
| 31 Dec 17 | 916 | 230 | 428 | 4 |
| 30 Sep 17 | 947 | 215 | 453 | 0 |
| 30 Jun 17 | 980 | 195 | 452 | 0 |
| 31 Mar 17 | 946 | 232 | 454 | 0 |
| 31 Dec 16 | 797 | 198 | 401 | 0 |
| 30 Sep 16 | 665 | 145 | 382 | 0 |
| 30 Jun 16 | 720 | 129 | 359 | 0 |
| 31 Mar 16 | 1,013 | 103 | 357 | 0 |
| 31 Dec 15 | 1,383 | 92 | 361 | 0 |
| 30 Sep 15 | 1,678 | 54 | 345 | 0 |
| 30 Jun 15 | 1,820 | 25 | 337 | 0 |
| 31 Mar 15 | 1,762 | 21 | 310 | 0 |
| 31 Dec 14 | 1,668 | 21 | 297 | 0 |
| 30 Sep 14 | 1,647 | 44 | 283 | 0 |
| 30 Jun 14 | 1,547 | 38 | 270 | 0 |
| 31 Mar 14 | 1,465 | 32 | 264 | 0 |
| 31 Dec 13 | 1,402 | 27 | 247 | 0 |
| 30 Sep 13 | 1,269 | 20 | 218 | 0 |
| 30 Jun 13 | 1,234 | 29 | 219 | 0 |
Quality Earnings: 600211 has high quality earnings.
Growing Profit Margin: 600211's current net profit margins (27.7%) are higher than last year (17.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600211's earnings have grown significantly by 20.8% per year over the past 5 years.
Accelerating Growth: 600211's earnings growth over the past year (62.7%) exceeds its 5-year average (20.8% per year).
Earnings vs Industry: 600211 earnings growth over the past year (62.7%) exceeded the Healthcare industry -1%.
Return on Equity
High ROE: 600211's Return on Equity (22.2%) is considered high.